


Appl. No. 10/775,464  
 Amdt. Dated September 6, 2005  
 Reply to Office Action of June 29, 2005

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1.(Currently Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof;

in which;

- a. M is NZ or  $\Theta^-$ ;
- b. Z is represented by H or C<sub>1</sub>-C<sub>4</sub> alkyl;
- c. R<sup>1</sup> is represented by hydrogen, (C<sub>1</sub>-C<sub>2</sub>)alkyl, optionally substituted with one or more halogens, or (C<sub>1</sub>-C<sub>2</sub>)alkoxy, optionally substituted with one or more halogens;
- d. R<sup>2</sup> is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, (C<sub>2</sub>-C<sub>4</sub>)alkynyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>2</sub>)alkyl substituted with one or more halogens, (C<sub>1</sub>-C<sub>2</sub>)alkoxy substituted with one or more halogens, SR<sup>4</sup>, and NR<sup>4</sup>R<sup>5</sup>;
- e. X is represented by O or S;

Appl. No. 10/775,464  
 Amdt. Dated September 6, 2005  
 Reply to Office Action of June 29, 2005

- f. A is represented by hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl,  $-\text{[CH}_2\text{]}_m\text{C(O)OR}^4$ ,  $-\text{[CH}_2\text{]}_m\text{C(O)R}^4$ ,  $-\text{[CH}_2\text{]}_m\text{C(O)NR}^4\text{R}^5$ ,  $-\text{[CH}_2\text{]}_m\text{-D-[CH}_2\text{]}_n\text{-CH}_3$ , or (CH<sub>2</sub>)<sub>n</sub>-R<sup>3</sup>-R<sup>6</sup>;
- g. D is O or S;
- h. m is an integer selected from 1 to 6;
- i. n is an integer from 0 to 6;
- j. R<sup>3</sup> is represented by optionally substituted phenyl, optionally substituted naphthyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;
- k. R<sup>4</sup> and R<sup>5</sup> are each independently represented by hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, optionally substituted benzyl or optionally substituted phenyl, and;
- l. R<sup>6</sup> is absent, or is represented by a substituent selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted phenoxy, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, optionally substituted heterocyclic, and optionally substituted heteroaryl.

Claim 2 (Cancelled).

Claim 3 (Original) The compound according to claim 2 in which Z is H.

Claim 4 (Cancelled).

Claim 5 (Original) The compound according to claim 1 in which R<sup>1</sup> is -CF<sub>3</sub>.

Claim 6 (Original) The compound according to claim 1 in which R<sup>2</sup> is absent.

Claim 7 (Original) The compound according to claim 1 in which X is O.

Claim 8 (Original) The compound according to claim 1 in which X is S.

Claims 9-11 (Cancelled).

Claim 13 (Original) A pharmaceutical composition comprising a compound according to Claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients.

Appl. No. 10/775,464  
Amdt. Dated September 6, 2005  
Reply to Office Action of June 29, 2005

Claim 14 (Original) A topical pharmaceutical formulation comprising a compound according to Claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.


Claim 15 (Currently Amended). ~~An kit article of manufacture~~ comprising a compound according to Claim 1 packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.

Claim 16 (New) A compound according to claim 1 selected from the group consisting of:  
1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenylurea;  
1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenylthiourea;  
1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(2-p-tolyethyl)thiourea;  
1-[2-(4-Chlorophenyl)ethyl]-3-(1-methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenyl-thiourea;  
1-Naphthalen-1-yl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-Cyclopropylmethyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydro-quinolin-6-yl)thiourea;  
1-[2-(3,4-Dimethoxyphenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-(2,4-Dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-(2,4-Dichlorophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-Furan-2-ylmethyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydro-quinolin-6-yl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-p-tolylthiourea;  
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(tetrahydrofuran-2-ylmethyl)thiourea;  
1-(2-Cyclohex-1-enylethyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-thiourea;  
1-(2-Isopropylphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(3-trifluoromethylphenyl)thiourea;

Appl. No. 10/775,464  
 Amdt. Dated September 6, 2005  
 Reply to Office Action of June 29, 2005

1-(5-Chloro-2,4-dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(4-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(4-Fluorophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(2-Methoxyethyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-thiourea;  
 1-Allyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(3-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(2-*p*-tolylethyl)thiourea;  
 1-Methyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-[2-(4-Chlorophenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-Isopropyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(4-Cyanophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;  
 1-(4-Methylbenzyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea; and  
 1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-*o*-tolylthiourea

Claim 17 (New ) A compound of the formula:



or a pharmaceutically acceptable salt thereof;

in which;

- M is O;
- R<sup>1</sup> is represented by -CF<sub>3</sub>
- R<sup>2</sup> is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, (C<sub>2</sub>-C<sub>4</sub>)alkynyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>2</sub>)alkyl substituted with one or more

Appl. No. 10/775,464  
 Amdt. Dated September 6, 2005  
 Reply to Office Action of June 29, 2005

halogens, (C<sub>1</sub>-C<sub>2</sub>)alkoxy substituted with one or more halogens, SR<sup>4</sup>, and NR<sup>4</sup>R<sup>5</sup>;

- d. X is represented by O or S;
- e. A is represented by hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>2</sub>-C<sub>8</sub>)alkenyl, (C<sub>2</sub>-C<sub>8</sub>)alkynyl,  $-\text{[CH}_2\text{]}_m\text{C(O)OR}^4$ ,  $-\text{[CH}_2\text{]}_m\text{C(O)R}^4$ ,  $-\text{[CH}_2\text{]}_m\text{C(O)NR}^4\text{R}^5$ ,  $-\text{[CH}_2\text{]}_m\text{-D-[CH}_2\text{]}_n\text{-CH}_3$ , or  $(\text{CH}_2)_n\text{-R}^3\text{-R}^6$ ;
- f. D is O or S;
- g. m is an integer selected from 1 to 6;
- h. n is an integer from 0 to 6;
- i. R<sup>3</sup> is represented by optionally substituted phenyl, optionally substituted naphthyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;
- j. R<sup>4</sup> and R<sup>5</sup> are each independently represented by hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, optionally substituted benzyl or optionally substituted phenyl, and;
- k. R<sup>6</sup> is absent, or is represented by a substituent selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted phenoxy, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, optionally substituted heterocyclic, and optionally substituted heteroaryl.

Claim 18 (New) A topical pharmaceutical formulation comprising a compound according to Claim 17 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

Claim 19 (new) A compound according to claim 16 selected from the group consisting of:  
 1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-phenylthiourea;  
 1-Naphthalen-1-yl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
 1-[2-(3,4-Dimethoxyphenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
 1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-trifluoromethoxyphenyl)urea;  
 1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-phenoxyphenyl)urea;

Appl. No. 10/775,464  
Amdt. Dated September 6, 2005  
Reply to Office Action of June 29, 2005

1-Furan-2-ylmethyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(4-Methoxybenzyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)-thiourea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-*p*-tolylthiourea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(tetrahydrofuran-2-ylmethyl)thiourea;  
1-(3-Isopropylphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-Benzo[1,3]dioxol-5-ylmethyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-trifluoromethylphenyl)thiourea;  
1-(4-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(2-Cyclohex-1-enylethyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(4-Fluorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(3,5-Dichlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;  
1-(4-Ethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;  
1-(3-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(2-*p*-tolylethyl)thiourea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-phenethylthiourea;  
1-[2-(4-Chlorophenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(4-Methoxy-2-methylphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;  
1-(4-Chlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;  
1-Hexyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;  
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-*o*-tolylthiourea;  
1-(4-Chlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea; and  
1-(2,4-Dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea.